Extension Study of MT-1303

PHASE2CompletedINTERVENTIONAL
Enrollment

367

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
DRUG

MT-1303-Low

DRUG

MT-1303-Middle

DRUG

MT-1303-High

Trial Locations (17)

Unknown

Research Site, City Name

Research Site, City Name

Research Site, City Name

Research Site, City Name

Research Site, City Name

Research Site, City Name

Research Site, City Name

Research Site, City Name

Research Site, City Name

Research Site, City Name

Research Site, City Name

Research Site, City Name

Research Site, City Name

Research Site, City Name

Research Site, City Name

Research Site, City Name

Research Site, City Name

All Listed Sponsors
lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY